|Will Cars Drive the Market?|
Will Cars Drive the Market?
By all accounts, it looks like we are in a bull market for new automobiles. This is surprising given the state of the economy and considering that vehicle prices are meaningfully higher. Plus, financing incentives are not as attractive as in recent years.
It appears that there are a few factors driving the market, including higher fleet sales to rental car companies and the resurgence of sub-prime auto lending. Still, the one factor which sticks out most prominently to us is a telling statistic:
The average age of vehicles on the road in the U.S. is 10.8 years, which is a record.
Clearly, the U.S. consumer is replacing older vehicles with newer ones, including those that provide better gas mileage which could be a one of the factors keeping the present (but shaky) bull market intact.
If this trend continues, I am going to make a prediction you will not see anywhere else, at least not for a few months.
If the stock market remains vibrant, it is Obama’s election to lose. If the auto business enjoys resurgence then stick a fork in the GOP. Battleground states that have a good deal of their economic fortunes tied to the automotive industry (e.g. Ohio) will wave the flag for current man in office. And if the housing market improves, it could be a cakewalk. Whether that is a good thing or a bad thing, I leave up to you.
Now, where is my passport…?
There is a way to play the auto market.
We recently recommended Autobytel (NASDAQ – ABTL.) As one of the leading online sources of information related to the purchase of automobiles, and a primary source of online consumer purchase requests and marketing resources to help car dealers and manufacturers sell cars, ABTL is uniquely positioned to benefit from the growth in auto sales in 2012.
In an interesting maneuver, management noted that while it will not likely comply with the NASDAQ $1 price rule, management believes that it will likely be granted an additional 180 days to meet the criteria of ten consecutive closes above the $1.00 mark. The Company stated it is exploring initiatives including a reverse split (not a fan here) and will likely make open market purchases this week, as part of its share buyback plan.
I do not ever recall a management team telegraphing such a transaction before.
In any event, we are unconcerned regarding the pricing issue and if ABTL is granted an extension, it would eliminate the current cap on the stock just north of the $1.00 mark and be a great catalyst for the stock.
Add that likelihood to the Company’s fundamentals, the fact that the industry is at its most favorable point in years, and the prospect of continued open market purchases by the Company is in the cards, and you have a stock that seems primed for a move higher.
Behind and Ahead
Last week we talked about the Yelp (NYSE – YELP) IPO and the misguided 13,000 DJIA and 3,000 NASDAQ Composite investor crazes fueled by the media. Yelp was a success although it did little to impact the rest of the market. Meanwhile, both the Dow and the NASDAQ Composite breached the “key” thresholds, and came right back down. Looks like narrow trading ranges are going to be with us a while longer.
If we were to brush away some of the external factors that impact trading, it seems that the market is nearing near term fair value, which lends further credence to our recent sentiment. The S&P 500 Index trades at around 13x FY12 EPS estimates while NASDAQ is just under 16x 2012 FY12 earnings. I think that most prognosticators would agree that fair value would probably top out a 15x S&P multiple and perhaps 18x NASDAQ.
Why Did NVLX Go Up?
I rarely provide commentary on our own reports and subsequent trading except to alert you to key snippets of information, in case you missed anything relevant to the companies in question. Nuvilex, Inc. (OTCQB – NVLX - $0.06) had a great week and we believe it is just the very beginning.
Clearly, investors are just starting to understand the value of the Company’s underlying live-cell encapsulation technology and delivery system and that when compared to other firms, the current valuation is exceedingly low.
In the pancreatic arena, Nuvilex should be compared with other firms that are presently at the Phase 2 clinical stage and other companies using encapsulation techniques. These firms, such as Threshold (NASDAQ – THLD) and Merrimack (private) have present or proposed (currently private) market values in the hundreds of millions.
In the diabetes treatment space, Nuvilex may have hit upon a holy grail. In animal models, the Firm’s live-cell encapsulation techniques may eliminate or substantially reduce the need for typical daily glucose checks and insulin injections. While a solid offering in its own right, the technology of its primary competitor is at the Phase I/IIa stage but does not appear to have as broad an application opportunity as Nuvilex.
Still, the market cap of this competitor, Living Cell Technologies (OTCQB – LVCLY) is over 70% higher than that afforded Nuvilex, which serves as further evidence that NVLX’s stock has much more room to grow.
Until next week…
Analyst: Robert Goldman
It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.
The Company has been compensated $8,000 by Nuvilex, Inc., for a research services engagement. The Firm has not been compensated nor does it expect to be compensated for the any research services for any of the other companies mentioned in this newsletter. Please read the disclaimers found on the initiation reports and updates for compensation disclosure and research subscription terms.
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This report or newsletter does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report or newsletter does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with the FINRA or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.
For more information, visit our Disclaimer: www.goldmanresearch.com.